7210 Wareham Drive, Tampa, FL 33647
May 9, 2024 Novo Nordisk is beginning work on a follow-up weight loss medicine that would last longer and could be manufactured more easily. On Thursday, the company unveiled a research project aimed at adding up to two more obesity treatments to its large pipeline, which already includes a long list of experimental obesity drugs […]
Novo Nordisk Working On Even Better Weight Loss Drugs Read More »
May 9, 2024 John LaRosa, Marketdata’s Research Director and founder, was recently interviewed by Kimberly Adams at Marketplace, a business and economic program, along with several others, about how the weight loss market is changing currently, being affected by the hugely popular GLP-1 weight loss medications. Here’s the interview, on audio. Click this link to
How GLP-1 Drugs Are Changing The Weight Loss Market – Podcast Read More »
May 2, 2024 Management reported that: “We delivered solid performance in the first quarter with end of period subscribers of 4.0 million, improved retention and engagement in our core business, and continued strong growth in our clinical business with 91 thousand end of period clinical subscribers,” said Sima Sistani, the Company’s CEO. “We continue to
Weight Watchers Reports Q1 Results Read More »
April 29, 2024 Management said that: “Our new model is highly differentiated from competitors, with a holistic approach including our habit-based and Coach guided solution along with nutrition products and community support. It will be supported by a reimagined framework for customer acquisition, with a new company-led national marketing campaign, enhancing both awareness of the
Medifast Reports Q1 2024 Results Read More »
April 29, 2024 According to an article at Biospace.com, GLP-1 agonists are set to become the best-selling drugs in 2024, but the biopharma industry isn’t resting on its collective laurels. Instead, some companies are pushing to improve upon the popular obesity medicines with therapies that promote higher-quality weight loss. Clinical studies have shown that up
Higher Quality Weight Loss Drugs Coming in the Future Read More »
April 13, 2024 Marketdata LLC (parent company of DietBusinessWatch) has just released new research, a report entitled: “The Telehealth Weight Loss Market”. The market for weight loss programs delivered via telehealth / telemedicine companies is worth $6.9 billion, and growing. Telehealth soared during the pandemic in 2020 as consumers stayed home and communicated with their
Telehealth Weight Loss Market Worth $6.9 Billion And Growing Read More »
March 19, 2024 Last night Oprah Winfrey hosted a TV special investigating the popular GLP-1 diet drugs. The stories by people who lost significant weight were good, as was the information about obesity being a disease and not just a lack of willpower. However, in our opinion, some very important topics were not even mentioned.
Oprah’s TV Special Falls Short Read More »
March 14, 2024 The U.S. pharmaceutical giant Eli Lilly is partnering with Amazon to help distribute its prescription drugs, notably its new weight loss treatment called Zepbound. Eli Lilly is using Amazon Pharmacy to distribute Zepbound to people’s homes through the drug maker’s new direct-to-consumer program. Going forward, Amazon Pharmacy will deliver drugs from Eli
Eli Lilly Offers Access To Zepbound via Amazon Read More »
March 4, 2024 U.S. Weight Loss Market Now Worth $90 Billion, Obesity Drug Sales Soar March 4, 2024 Marketdata LLC has just published a new analysis of the weight loss market: “The U.S. Weight Loss Market: 2024 Status Report & Forecast”, March 2024, 107 Pages Some findings: The total U.S. weight loss market is estimated
U.S. Weight Loss Market Worth $90 Billion, Boosted by Diet Drugs Read More »
Feb. 28, 2024 WW reported its results for Q4 2023 and the full year today. WW reported results in line with analysts’ expectations in Q4 FY2023, with revenue down 8% year on year to $206 million. “2023 was a pivotal year as we began transforming our business for the future. We returned WeightWatchers to year
Weight Watchers Reports Q4 and 2023 Results Read More »